Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis

Basit Öğe Kaydı
dc.authorid0000-0002-4641-2866en_US
dc.authorid0000-0003-1710-7018en_US
dc.authorid0000-0002-3495-2339
dc.contributor.authorKurt, Özlem Kar
dc.contributor.authorKurt, Bahar
dc.contributor.authorTalay, Fahrettin
dc.contributor.authorTuğ, Tuncer
dc.contributor.authorSoy, Mehmet
dc.contributor.authorBes, Cemal
dc.contributor.authorHayran, Mutlu
dc.date.accessioned2021-06-23T19:34:13Z
dc.date.available2021-06-23T19:34:13Z
dc.date.issued2013
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractThe use of anti-TNF drugs for rheumatic diseases has increased in recent years. Several studies have reported an increased risk of reactivation of tuberculosis (TB) with anti-TNF agents. The aim of this study was to present the follow-up results of a single center from Turkey, a country with a high rate of active and latent tuberculosis infection (LTBI), for INH chemoprophylaxis in patients receiving anti-TNF-alpha therapy for rheumatic diseases infection. In this prospective observational study, consenting patients who were to be administered an anti-TNF agent for a rheumatic disease were evaluated for the presence of active infection or LTBI by a chest X-ray and a tuberculin skin test. Patients with LTBI were given chemoprophylaxis 1 month prior to commencement of anti-TNF treatment. All patients were followed-up bimonthly for any signs of pulmonary or extrapulmonary TB. A total of 73 patients, 23 female (31.5 %) and 50 male (68.5 %), with a mean age of 41.0 +/- A 13.1 years (18-78) were enrolled in the study. Overall, 44 patients (60.3 %) had ankylosing spondylitis, 18 (24.7 %) had rheumatoid arthritis, 7 (9.6 %) had juvenile rheumatoid arthritis, and 3 (4.1 %) had psoriatic arthritis. LTBI was identified in 58 patients all of whom received chemoprophylaxis for 9 months. None of the patients in the study developed any signs of tuberculosis reactivation during follow-up. TST is a reliable and cost-effective method for the diagnosis of LTBI in patients prior to anti-TNF therapy. Moreover, chemoprophylaxis with INH seems to be effective for the prevention of TB reactivation in individuals with LTBI.en_US
dc.identifier.doi10.1007/s00508-013-0417-0
dc.identifier.endpage620en_US
dc.identifier.issn0043-5325
dc.identifier.issn1613-7671
dc.identifier.issue19-20en_US
dc.identifier.pmid24061693en_US
dc.identifier.scopus2-s2.0-84886949514en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage616en_US
dc.identifier.urihttps://doi.org/10.1007/s00508-013-0417-0
dc.identifier.urihttps://hdl.handle.net/20.500.12491/7431
dc.identifier.volume125en_US
dc.identifier.wosWOS:000325850800005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKurt, Özlem Kar
dc.institutionauthorKurt, Bahar
dc.institutionauthorTalay, Fahrettin
dc.institutionauthorTuğ, Tuncer
dc.language.isoenen_US
dc.publisherSpringer Wienen_US
dc.relation.ispartofWiener Klinische Wochenschriften_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-TNF-Alpha Drugsen_US
dc.subjectChemoprophylaxisen_US
dc.subjectTuberculosisen_US
dc.titleIntermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
ozlem-kar-kurt-7431.pdf
Boyut:
294.92 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu